EUVIMEDEUVIMED entdecken
Crossref

L26/P-886 Fertility treatment in WHO type II anovulation: perinatal risks driven by treatment or condition?

M. Van Wely, T. Jannink, E. Bordewijik, N. Weiss, L. Broeders, A. Hoek, M. Goddijn

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Van Wely und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Do fertility treatments, including ovulation induction and assisted reproductive techniques, influence perinatal outcomes in singleton live births of women with WHO type II anovulation? Summary answer Singletons born after gonadotropins had increased risk of low birthweight, while no other differences in perinatal outcomes were observed for clomiphene citrate, gonadotropins, or IVF/ICSI. What is known already Women with WHO type II anovulation, often due to PCOS, frequently require fertility treatments such as ovulation induction or assisted reproductive techniques. Previous studies suggest these treatments may influence perinatal outcomes. However, PCOS itself is also associated with adverse perinatal outcomes. Most studies have compared perinatal outcomes after fertility treatment with those in women without infertility, potentially overlooking risks related to the underlying condition. To our knowledge, no previous study has compared perinatal outcomes after fertility treatment with natural conception within women with WHO type II anovulation. Study design, size, duration We conducted a prospective cohort study using follow-up data from the M-OVIN randomised trial in women with WHO type II anovulation. The original trial included 666 women from 48 Dutch hospitals and compared clomiphene citrate (CC) with FSH, with or without IUI, in women with CC failure. Follow-up between 2020 and 2022 involved 374 women (median follow-up 8 years) through web-based questionnaires. Perinatal outcomes were obtained by linking participants to the Dutch national perinatal registry. Participants/materials, setting, methods The study included singleton live births conceived during the trial or follow-up. Outcomes were compared by as-treated conception method: natural conception (reference), ovulation induction with CC (with or without IUI), ovulation induction with FSH (with or without IUI), and IVF/ICSI. Primary outcomes were mean birthweight (grams) and birthweight percentiles. Secondary outcomes included low or high birthweight, SGA and LGA, preterm birth, neonatal adverse outcomes (Apgar <7, NICU admission, congenital anomalies), and pregnancy complications. Main results and the role of chance We analysed 460 singleton pregnancies resulting in live births, which were conceived by 279 women. Of these, 142 were conceived after natural conception, 105 after CC, 138 after FSH, and 75 after IVF/ICSI. Mean birthweight and birthweight percentiles did not differ significantly between treatment groups and natural conception after adjustment for confounders. Ovulation induction with FSH was associated with an increased risk of low birthweight (<2500 g) (5.1% vs 2.8%, adjusted RR 3.70, 95% CI 1.03 - 13.28). No treatment group showed an increased risk of SGA, HBW, LGA, preterm birth, gestational hypertensive disorders, or gestational diabetes. Neonatal adverse outcomes were rare, with no evidence of increased risk in any group. Limitations, reasons for caution The findings are limited by the number of cases. Wider implications of the findings Our study suggests fertility treatments, including OI with CC or FSH and IVF/ICSI, do not substantially increase most adverse perinatal risks in Dutch women with WHO type II anovulation. These findings emphasize the importance of considering underlying parental factors when interpreting perinatal outcomes after fertility treatment. Larger studies are needed. Trial registration number No

Zitieren

APA

Wely, M. V., Jannink, T., Bordewijik, E., Weiss, N., Broeders, L., Hoek, A., & Goddijn, M. (2026). L26/P-886 Fertility treatment in WHO type II anovulation: perinatal risks driven by treatment or condition?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1210

Vancouver

Wely MV, Jannink T, Bordewijik E, Weiss N, Broeders L, Hoek A, et al. L26/P-886 Fertility treatment in WHO type II anovulation: perinatal risks driven by treatment or condition?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1210

BibTeX
@article{Wely2026,
  author = {Wely, M. Van and Jannink, T. and Bordewijik, E. and Weiss, N. and Broeders, L. and Hoek, A. and Goddijn, M.},
  title = {L26/P-886 Fertility treatment in WHO type II anovulation: perinatal risks driven by treatment or condition?},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1210}
}
Kostenlos starten →